SPACInsider Logo
Act II Global Acquisition Corp. (ACTT) Gets a $75M PIPE
by Kristi Marvin on 2020-02-12 at 9:31pm

And Amends the Public Warrants.

Act II Global Acquisition Corp. (ACTT), announced today that it has entered into a private placement transaction, at a $10.00 per share “benchmark“, with a consortium of investors and accounts led by institutional investor Baron Small Cap Fund for gross proceeds of $75 million. However, “benchmark” is an interesting term. We only have a press release to go by right now, so we’ll have to wait and see if that term is meaningful of something other than $10.00, or a “benchmark” for something else.

In the meantime, there were additional changes to the deal as well. Per the press release:

Substantial Reduction in Dilutive Securities

  • Following the closing, the Sellers will no longer receive the previously agreed 1.0 million shares in escrow
  • the Sellers will also forfeit their contingent right to any additional earnout consideration, which had totaled up to approximately 2.7 million shares;
  • Act II Global LLC (the “Sponsor”) will forfeit 3.0 million Class B ordinary shares;
  • 61% of the Sponsor’s private placement warrants will be eliminated at the closing of the business combination;
  • as a condition to the parties’ obligations to complete the private placement, Act II will amend all other publicly-held warrants so that each such warrant holder will receive, following the closing of the business combination a cash payment of $0.75 per warrant (with the Sponsor and the private placement investors waiving the right to any such cash payment) and the warrant will be exercisable for one-half of a Class A ordinary share for an exercise price of $5.75 for each one-half share ($11.50 per whole share), effectively eliminating 50% of the dilution from the public warrants.

Improved Leverage Profile

  • Net leverage following the consummation of the private placement and warrant amendment is expected to be approximately 2.0x, as opposed to 3.0x as previously announced.

The most notable change probably being to the publicly held warrants, which eliminates half of the public warrants, bringing the public overhang to a 1/4 warrant. However, the Sellers and Act II have re-struck their deal in an effort to make this deal more attractive as well.  Specifically, the sponsors are cancelling 3.0 million of their original 7.5 million founder shares, or 40% of their total. Plus, 61% or their at-risk private placement purchase of warrants.  That’s a big cut.  As for the sellers, they’re eliminating their contingent earnout and the 1.0 million shares in escrow.

However, let’s see what the filed documents have to say about the PIPE “benchmark” price of $10.00 before we fully evaluate these changes.  It could mean nothing or it could mean something.  It looks good so far, but let’s wait for the docs and see.


Recent Posts
by Marlena Haddad on 2022-12-01 at 11:25am

  Below is a daily summary of links to the latest SPAC news and rumors gathered across the web.  Latest SPAC News:  NYSE president says IPO proceeds fall more than 90% while Nasdaq president remains hopeful for 2023, and Giuliani brothers sell pharma stocks as they invest in biotech SPACs NYSE president says IPO proceeds fall...

by Marlena Haddad on 2022-12-01 at 10:02am

InterPrivate II Acquisition Corp. (NYSE:IPVA) disclosed this morning that it has restructured its bonus share agreement in connection to its proposed merger with carsharing marketplace Getaround. The parties previously agreed to reserve and set aside the bonus shares, consisting of 9,333,333 shares, to be allocated to the non-redeeming public stockholders, the designees of EarlyBirdCapital and the...

by Nicholas Alan Clayton on 2022-12-01 at 9:31am

Iris Acquisition Corp. (NASDAQ:IRAA) has entered into a definitive agreement to combine with biotech firm Liminatus at an enterprise value of $334 million. La Palma, California-based Liminatus is a clinical-stage drug developer working on a range of cancer treatments utilizing both preventative vaccines and CAR-T therapies. The combined company is expected to trade on the...

by Marlena Haddad on 2022-12-01 at 9:22am

Lakeshore Acquisition Corp. I (NASDAQ:LAAA) announced this morning that it has entered into a non-redemption agreement and amended its purchaser support agreement with initial shareholders in connection to its proposed merger with medical device company ProSomnus. The SPAC entered into non-redemption agreements with certain institutional investors for an aggregate of 200,339 shares of the purchaser. These investors...

by Nicholas Alan Clayton on 2022-11-30 at 6:01pm

The companies and sponsors of six SPAC deals are set to see their lock-ups expire before the end of the year. This is a relatively small monthly total as the wave of deals from 2020 and 2021 are still hitting this milestone. The list nonetheless includes some major names starting with Forafric (NASDAQ:AFRI), which is...

Privacy Policy|Terms Of Use
Copyright © 2022 SPACInsider, Inc. All Rights Reserved